RLFTF (RLFTF) Stock Price & Analysis
RLFTF (RLFTF) fell 7.52% to USD 0.42 as of June 10, 2026 at 07:16 UTC, according to Nexqual real-time market data.
RLFTF last closed at USD 0.45; the session ranged USD 0.42–0.42 on volume of 10 shares. Market capitalization is $5.28M, with a 52-week range of USD 0.33–4.88 (OQB). Source: Nexqual, June 10, 2026 at 07:16 UTC.
Key Statistics (as of June 10, 2026 at 07:16 UTC)
| Price | USD 0.42 |
|---|---|
| Change | ▼ 7.52% (down) |
| Previous Close | USD 0.45 |
| Open | USD 0.42 |
| Day Range | USD 0.42 – 0.42 |
| 52-Week Range | USD 0.33 – 4.88 |
| Volume | 10 shares |
| Market Cap | $5.28M |
| Exchange | OQB |
Technical Analysis (RLFTF)
Nexqual's technical model rates RLFTF "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 07:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.13 (neutral) |
| vs SMA50 | Below (USD 0.46) |
| MACD | -0.01 (negative) |
Analyst Ratings (RLFTF)
Wall Street analysts rate RLFTF "None", per Nexqual as of June 10, 2026 at 07:16 UTC.
| Consensus Rating | None |
|---|
Earnings (RLFTF)
Source: Nexqual, June 10, 2026 at 07:16 UTC.
Financials & Fundamentals (RLFTF)
| Total Revenue | $642,000 |
|---|---|
| Gross Margin | +92.06% |
| Operating Margin | -1637.85% |
| Profit Margin | +0.00% |
| ROE | -51.56% |
| Current Ratio | 1.2 |
Source: Nexqual, June 10, 2026 at 07:16 UTC.
Financial Health Score (RLFTF)
Nexqual rates RLFTF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -52%, ROA -25.5% |
Ownership (RLFTF)
| Insider Ownership | +55.03% |
|---|---|
| Institutional Ownership | +26.06% |
| Shares Outstanding | 12.59M |
| Float | 52.40M |
Source: Nexqual, June 10, 2026 at 07:16 UTC.
Leadership (RLFTF)
RLFTF is led by Zachery W. Henderson (age 52), Chief Executive Officer, per Nexqual as of June 10, 2026 at 07:16 UTC.
| Chief Executive Officer | Zachery W. Henderson (age 52) |
|---|---|
| Chief Financial Officer | Jeremy Meinen (age 36) |
| Chief Operating & Strategy Officer | Alexandre Capet (age 52) |
| Chief Technology Officer | Frédéric Condolo (age 52) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYDY | CytoDyn Inc. | USD 0.3 | ▲ 1.72% |
| RVVTF | Revive Therapeutics Ltd. | USD 0.03 | ▲ 15.45% |
| NRXP | NRX Pharmaceuticals, Inc. | USD 3.87 | ▼ 6.52% |
| OPTI | Optec International, Inc. | USD 0 | ▼ 25% |
| ENZC | Enzolytics Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:16 UTC. This page is informational and not investment advice.